15 results about "Angiogenesis Factor" patented technology

The invention discloses a black phosphorus hydrogel microneedle patch loaded with trained mesenchymal stem cells as well as a preparation method and application of the black phosphorus hydrogel microneedle patch, and belongs to the technical field of biological medicines. The micro-needle patch comprises a hydrogel substrate layer loaded with black phosphorus nanosheets and a hydrogel needle tip part for packaging the stem cells. The mesenchymal stem cells are subjected to combined domestication with low oxygen and high active oxygen, so that the anti-oxidative stress, anti-inflammatory and angiogenesis promoting capabilities of the mesenchymal stem cells are remarkably enhanced. After the patch is subcutaneously delivered, the black phosphorus component can efficiently remove bacteria and reduce drug resistance; after being domesticated, the stem cells can adapt to the immune microenvironment of the wound surface, and the immune regulation, inflammation inhibition and tissue regeneration promotion are synergistically realized by continuously releasing anti-inflammatory and angiogenesis promoting factors, so that the refractory wound surface caused by immune disorders such as systemic lupus erythematosus (SLE) and the like is effectively treated. The invention provides an innovative treatment strategy for chronic inflammatory wound healing.

This invention provides an antibody fusion protein comprising a binding construct that targets and is capable of binding to Ang-2, IL-6 receptors, and at least one VEGF family member; or an antigen-binding fragment or domain of the antibody fusion protein. The antibody fusion protein comprises an antibody or binding peptide against Ang-2, an antibody against IL-6R, and multiple extracellular domains of the VEGF receptor as binding components. The antibody fusion protein is suitable for treating or controlling ocular or systemic diseases, symptoms, or conditions caused by abnormal angiogenesis, increased vascular leakage, or inflammation.

A biologic composition for promoting wound healing includes: a human mesenchymal stem cell (MSC)-derived extracellular matrix (ECM) biologic component, and a negatively charged polymer, combined with the biologic component to form the biologic composition. A method of preparing the biologic composition thereof includes: (i) isolating human mesenchymal stem cells (MSC) and subjecting the MSC to hypoxia-priming in a xeno- and / or serum-free, or chemically defined medium to stimulate the production of an MSC-derived biologic component with pro-angiogenic factors; (ii) aggregating and co-precipitating the MSC-derived biologic component with a negatively charged polymer into a pericellular space of the MSC to produce an aggregated biologic component; (iii) assembling the aggregated biologic component and the negatively charged polymer into an insoluble extracellular matrix (ECM) by the MSC; and (iv) decellularizing the insoluble ECM to obtain the biologic composition comprising MicroParticles of Solidified Secretome (MIPSOS).

The invention discloses a novel coaxial electrostatic spinning stent coupling piezoelectric stimulation and AVT, the morphology of the stent simulates an extracellular matrix, adhesion, growth and differentiation of cells are facilitated, and a space is provided for growth of new blood vessels and new bones; the coaxial electrostatic spinning stent takes an artificial high polymer material as a matrix, is good in biological safety and can be degraded in vivo, and a degradation product is non-toxic; a clinical drug AVT for promoting angiogenesis is loaded in a fiber shell layer, and the defects that various angiogenesis promoting factors are high in price, short in half-life period, insufficient in potential safety and the like are overcome; the piezoelectric material ZnO for promoting osteogenic differentiation is loaded on the fiber core layer, various defects of external electrical stimulation equipment are avoided, the osteogenic differentiation is continuously promoted by collecting masticatory muscle force and converting the masticatory muscle force into piezoelectric stimulation, meanwhile, angiogenesis is promoted in combination with early release of AVT, and finally, vascularized bone regeneration of lower jawbone defects is promoted. According to the invention, the source of required materials is sufficient, the preparation technology is simple, the cost is low, the biological safety is good, and the potential clinical application prospect is achieved.

The invention discloses cell-free fat extract loaded GelMA hydrogel and skin flap survival application, and particularly relates to the technical field of biomedical engineering. The hydrogel is prepared from GelMA, Ceffe, lithium phenyl (2, 4, 6-trimethylbenzoyl) phosphonate and a phosphate buffer salt solution. Wherein the Ceffe is rich in a plurality of angiogenesis promoting factors and is obtained through physical emulsification and centrifugal extraction; gelMA is prepared by modifying pig A-type gelatin through methacrylic anhydride, and has temperature-sensitive and photo-crosslinking characteristics. The injectable hydrogel with a porous network structure is formed by mixing Ceffe and a GelMA solution and curing through ultraviolet irradiation. The compound system realizes Ceffe biphasic slow release, remarkably promotes proliferation, migration and tube formation of vascular endothelial cells in vivo and in vitro, improves the survival rate of random skin flaps of mice, and effectively relieves oxidative stress injury caused by ischemia reperfusion by up-regulating HO-1 and down-regulating INOS.

The invention discloses application of antisense nucleotide for inhibiting NEAT1 in a targeted parasite assembly domain to treatment, improvement or prevention of fundus neovascularization, and belongs to the technical field of biological medicine. The invention finds that NEAT1 and downstream pro-angiogenesis factors CYR61 and FGF2 are obviously up-regulated in wet age-related macular degeneration patients and CNV model mice. According to the invention, the NEAT1 in the retina and the choroid is efficiently inhibited by designing ASO of a specific targeting lncRNA NEAT1 functional key domain, namely, a para-plaque assembly domain. Furthermore, ASO of a targeted mouse Neat1 homologous domain is subjected to intraocular injection, and laser-induced CNV focus formation can be remarkably inhibited in vivo. The invention provides a candidate drug for treating fundus neovascularization, which is independent of the traditional VEGF pathway and novel in action mechanism, and provides a new solution for patients who are insensitive to anti-VEGF therapy or need long-acting treatment.

This invention provides a biomarker for collateral circulation in CTO patients, MIA3, and its application, belonging to the field of biotechnology. This invention reveals and verifies a significant positive correlation between plasma MIA3 levels and the quality of collateral circulation formation in CTO patients, and its predictive efficacy for good collateral circulation is superior to that of the known key angiogenesis factor VEGFA. This allows MIA3 to serve as a high-value, minimally invasive molecular marker for early, non-invasive identification of a patient's collateral circulation formation potential before interventional surgery, thereby enabling risk stratification and providing an objective basis for individualized treatment decisions (such as whether more aggressive intervention is needed). This invention clarifies that MIA3 is a key link in regulating collateral angiogenesis; by targeting and upregulating MIA3 activity, collateral angiogenesis and maturation in ischemic areas can be precisely promoted, providing a novel non-pharmacological, non-surgical treatment strategy for CTO patients.

This invention relates to the field of medical data analysis, and more particularly to a method for assessing the risk of pregnancy outcomes in pregnant women based on multifactor feature analysis. The method includes: acquiring individual measured time-series datasets and baseline reference data for physiological expectations; obtaining a gestational age-specific pathological surge penalty factor by weighting the ratio of angiogenic factors to anti-angiogenic factors; obtaining a cross-system pathological cascade time coupling factor by temporally tracing and coupling abnormal deviations in vascular system indicators and blood system indicators; obtaining a fused feature vector by correcting and fusing the initial linear regression slope features; and obtaining the pregnancy outcome risk assessment result by performing machine learning prediction on the fused feature vector. This method solves the problem that existing prediction methods based on linear regression slope extraction and feature splicing cannot effectively identify gestational age-specific early high-risk signals and cross-system short-term pathological cascade signals.

The application belongs to the field of biological medicine, and provides application of TGF-beta / Smad signal pathway in treatment of corneal neovascularization after corneal alkali burn. The application proves that by inhibiting the TGF-beta / Smad signal pathway, the alkali burn-induced corneal neovascularization can be significantly reduced, and the corneal pathological damage is improved, and the mechanism of action involves regulating M2 type macrophage polarization and inhibiting the process of cellular ferroptosis of corneal tissue. It is found that by using a specific inhibitor SB-431542, the expression of TGF-beta1 and p-Smad2 / 3 proteins can be effectively reduced, the angiogenic factors such as VEGFA and CD31 are reduced, the inflammatory factors such as IL-4 and IL-10 are down-regulated, the GSH level is restored, and the Fe 2+ and MDA contents are reduced. The application is suitable for developing a targeted therapeutic drug for pathological neovascularization after corneal alkali burn, and provides a theoretical basis.

The invention discloses a preparation method and application of VEGF (vascular endothelial growth factor) engineered endothelial extracellular vesicles. The invention provides a specific preparation method, VEGF engineered endothelial extracellular vesicles (vEVs) and pharmaceutical application of the VEGF engineered endothelial extracellular vesicles. Compared with untreated common endothelial extracellular vesicles (EVs), the yield of the vEVs prepared by the invention is higher, and the vEVs are rich in higher-level angiogenesis promoting factors such as VEGF (vascular endothelial growth factor) and the like, show remarkably enhanced endothelial cell migration and tube formation promoting capability and accelerate endothelial cell uptake efficiency. The invention can be used for preparing medicines for promoting tissue repair and revascularization, and particularly has wide application prospects in the fields of diabetes wound healing, ischemic disease treatment and the like.

A fusion protein comprises two VEGF-binding units, a least one of which comprises at least an extracellular domain of at least a VEGF receptor. The other VEGF-binding unit can comprise a VEGF-C antibody or at least a different extracellular domain of at least a VEGF receptor. The fusion protein can further comprise an Ang-2-binding unit. The fusion protein is useful in treating or controlling an ocular or systemic disease, condition, or disorder that has etiology in at least one of aberrant angiogenesis, increased vascular leakage, and inflammation.

This application discloses a multispecific fusion protein comprising a binding construct that targets and is capable of binding to at least one of DLL4 and VEGF family members; or an antigen-binding fragment or domain thereof. This application also discloses a multispecific fusion protein comprising an antibody against DLL4 or an antigen-binding fragment thereof, multiple extracellular domains of the VEGF receptor or an antibody against at least one VEGF family member or an antigen-binding fragment thereof, and an antibody or binding peptide against Ang-2. The multispecific fusion protein can be used to treat or control ocular or systemic diseases, conditions, or disorders caused by abnormal angiogenesis, increased vascular leakage, inflammation, fibrosis, or combinations thereof.

A biological composition for promoting wound healing includes: a human mesenchymal stem cell (MSC)-derived extracellular matrix (ECM) biological component; and a negatively charged sulfated polymer; wherein the negatively charged polymer is combined with the biological component to form the biological composition. A method of preparing a biological composition for promoting wound healing comprises: (i) isolating human mesenchymal stem cells (MSCs) and subjecting the MSCs to hypoxia pretreatment in a culture medium to stimulate secretion of MSC-derived biological components containing pro-angiogenic factors; (ii) aggregating and co-precipitating the MSC-derived biological component with a negatively charged polymer in the pericellular space of the MSC to produce an aggregated biological component; (iii) assembling, by the MSC, the aggregated biological component and the negatively charged polymer into an insoluble ECM; and (iv) subjecting the insoluble ECM to a decellularization treatment to obtain the biological composition comprising solidified secretory group microparticles (MIPSOS). The biological composition exhibits excellent therapeutic efficacy, in particular, faster wound healing speed and stronger angiogenic bioactivity.

The invention belongs to the technical field of biology, and particularly relates to application of Pt5-1c in preparation of a medicine for promoting angiogenesis and accelerating wound healing. It is found for the first time that Pt5-1c can effectively promote angiogenesis in vitro and in vivo. The invention relates to a novel compound which enhances endothelial cell functions, accelerates mouse vascular repair and rescues vascular defects of zebrafish, these effects are mediated by a pleiotropic mechanism, including up-regulation of pro-angiogenic factors and activation of PI3K / AKT / mTOR and p38 MAPK signaling pathways, and in combination with established safety characteristics and validated efficacy in tissue repair, the compound can be used for preparing a novel compound, and the compound can be used for preparing a novel compound. Pt5-1c represents a regenerative therapeutic agent with a prospect.

To discover an ingredient having an angiogenic factor production promoting action from specific plants, create a novel angiogenic factor production promoter comprising such a component as an active ingredient, and blend the active ingredient in a topical skin preparation or a scalp cosmetic to be utilized for sound hair growth.SOLUTION: An angiogenic factor production promoter comprises Senecio herreanus f.variegata extract as an active ingredient, which is used to prepare a topical skin preparation such as a scalp cosmetic capable of promoting the production of a vascular endothelial growth factor (VEGF) and a basic fibroblast growth factor (bFGF).SELECTED DRAWING: None